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Summary
Background By contrast with many observational studies, women in the Women’s Health Initiative (WHI) trial who 
were randomly allocated to receive oestrogen alone had a lower incidence of invasive breast cancer than did those who 
received placebo. We aimed to assess the inﬂ uence of oestrogen use on longer term breast cancer incidence and 
mortality in extended follow-up of this cohort.
Methods Between 1993 and 1998, the WHI enrolled 10 739 postmenopausal women from 40 US clinical centres 
into a randomised, double-masked, placebo-controlled trial. Women aged 50–79 years who had undergone 
hysterectomy and had expected 3-year survival and mammography clearance were randomly allocated by a 
computerised, permuted block algorithm, stratiﬁ ed by age group and centre, to receive oral conjugated equine 
oestrogen (0·625 mg per day; n=5310) or matched placebo (n=5429). The trial intervention was terminated early 
on Feb 29, 2004, because of an adverse eﬀ ect on stroke. Follow-up continued until planned termination 
(March 31, 2005). Consent was sought for extended surveillance from the 9786 living participants in active follow-
up, of whom 7645 agreed. Using data from this extended follow-up (to Aug 14, 2009), we assessed long-term 
eﬀ ects of oestrogen use on invasive breast cancer incidence, tumour characteristics, and mortality. We used Cox 
regression models to estimate hazard ratios (HRs) in the intention-to-treat population. This study is registered 
with ClinicalTrials.gov, number NCT00000611.
Findings After a median follow-up of 11·8 years (IQR 9·1–12·9), the use of oestrogen for a median of 5·9 years 
(2·5–7·3) was associated with lower incidence of invasive breast cancer (151 cases, 0·27% per year) compared with 
placebo (199 cases, 0·35% per year; HR 0·77, 95% CI 0·62–0·95; p=0·02) with no diﬀ erence (p=0·76) between 
intervention phase (0·79, 0·61–1·02) and post-intervention phase eﬀ ects (0·75, 0·51–1·09). In subgroup analyses, 
we noted breast cancer risk reduction with oestrogen use was concentrated in women without benign breast disease 
(p=0·01) or a family history of breast cancer (p=0·02). In the oestrogen group, fewer women died from breast 
cancer (six deaths, 0·009% per year) compared with controls (16 deaths, 0·024% per year; HR 0·37, 95% CI 
0·13–0·91; p=0·03). Fewer women in the oestrogen group died from any cause after a breast cancer diagnosis 
(30 deaths, 0·046% per year) than did controls (50 deaths, 0·076%; HR 0·62, 95% CI 0·39–0·97; p=0·04).
Interpretation Our ﬁ ndings provide reassurance for women with hysterectomy seeking relief of climacteric symptoms 
in terms of the eﬀ ects of oestrogen use for about 5 years on breast cancer incidence and mortality. However, our data 
do not support use of oestrogen for breast cancer risk reduction because any noted beneﬁ t probably does not apply to 
populations at increased risk of such cancer.
Funding US National Heart, Lung, and Blood Institute; Wyeth.
Introduction
Elevated concentrations of endogenous oestrogen have 
been consistently associated with increased risk of 
breast cancer.1 Exogenous oestrogen use has also been 
associated with higher breast cancer incidence in many2–5 
but not all6,7 observational studies, especially in leaner 
women3–5,8 and those receiving oestrogen long term.4,5,8,9 
Oestrogen use has been linked to hormone-receptor 
positive and early stage disease,3,5 suggesting a better 
prognosis,10 although associations with breast cancer 
mortality are mixed.2,9,10–17
During the intervention phase of the Women’s Health 
Initiative (WHI) randomised trial17 of 10 739 post meno-
pausal women who had undergone hysterectomy, a non-
signiﬁ cant reduction in incidence of breast cancer was 
noted after receipt of conjugated equine oestrogens 
compared with placebo (hazard ratio [HR] 0·79, 95% CI 
0·61–1·02). After trial intervention was stopped in 
February, 2004, because of an increased incidence of 
stroke,18 follow-up continued until planned termin-
ation in 2005 and every year thereafter for participants 
who consented to extended surveillance. Results of a 
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prespeciﬁ ed analysis in 2009 suggested that most 
estimates of the eﬀ ect of oestrogen on risk of chronic 
disease were attenuated. The reduced breast cancer risk 
in the oestrogen group persisted and reached statistical 
signiﬁ cance (HR 0·77, 95% CI 0·62–0·95).19 We aim to 
provide additional details about the eﬀ ects of oestrogen 
use on invasive breast cancer incidence during and after 
intervention with regard to tumour characteristics and 
previously identiﬁ ed eﬀ ect modiﬁ ers. We also present 
results for breast cancer-related mortality.
Methods
Study design and participants
Postmeno pausal women aged 50–79 years who had 
under gone a hysterectomy were recruited into the WHI 
randomised, double-masked, placebo-controlled trial 
at 40 clinical centres in the USA between 1993 and 
1998. Previous breast cancer was an exclusion criterion 
and clearance by recent mammograms and clinical breast 
examinations was required. Women who were taking 
hormones underwent a 3-month washout period. Eligible 
women were randomly allocated in a one-to-one ratio to 
receive oral conjugated equine oestrogen (0·625 mg per 
day) or matched placebo through use of a computerised, 
permuted-block algorithm, stratiﬁ ed by age group and 
centre. Randomisation and drug dispensing was 
supported through a secure database system developed 
and implemented by the WHI Clinical Coordinating 
Center (Seattle, WA, USA). Clinical centre staﬀ  entered 
the eligibility data into the database and executed a 
database function that conﬁ rmed eligibility and did the 
randomisation. Double-masking was imple mented 
through an associated database drug dispensing system. 
The study was approved by each centre’s institutional 
review board. All women provided written informed 
consent. Details of study design, eligibility, and 
implementation have been published elsewhere.18,19
Data collection
Participants’ previous hormone use was ascertained at 
baseline by an interviewer-administered questionnaire. 
Medical, reproductive, and family histories were obtained 
by self-reported questionnaires. Height and weight were 
measured by study staﬀ . All non-study drug use was 
assessed by interviewer-administered questionnaire at 
baseline and follow-up at 1, 3, 6, and 9 years. Adherence to 
study drug was assessed primarily by pill counts or 
weighing returned bottles; self-report was used only rarely.
Until 2005, participants’ vital and health status was 
assessed twice every year and mammography was done 
once per year throughout the trial. When the intervention 
ended on Feb 29, 2004, after a mean follow-up of 
7·1 (SD 1·6) years, all participants were unmasked and 
asked to stop taking the study drug. Follow-up continued 
according to the original protocol until the planned study 
end (March 31, 2005). During study close-out, 
7645 participants (78% of 9786 living participants in active 
follow-up at that time; 3778 [77·9%] of 4851 women 
allocated to oestrogen and 3867 [78·4%] of 4935 allocated 
to placebo) consented to extended follow-up.19 From 2005, 
vital and health status updates have been obtained once 
per year. This report presents data until Aug 14, 2009, after 
an overall median follow-up of 11·8 years (IQR 9·1–12·9).
Breast cancers were documented by medical and 
pathological record review by centrally trained doctor 
adjudicators. Tumour characteristics were coded at 
the WHI Clinical Coordinating Center according to 
Surveillance, Epidemiology, and End Results (SEER) 
guidelines.20 Deaths were documented with death 
certiﬁ cates and medical records. We searched the national 
death index to identify deaths in participants lost to 
follow-up through Dec 31, 2008. Central doctor 
adjudicators reviewed medical records to establish causes 
of death. All adjudicators were masked to randomisation 
assignment.
Statistical analysis
We compared incidence of breast cancer by treatment 
group with failure-time methods and the intention-to-
treat principle. We calculated HR and 95% CIs from 
Cox regression models, stratiﬁ ed by age group and 
randomisation assignment in the concurrent WHI dietary 
modiﬁ cation trial. We did analyses for three time phases: 
the intervention phase (from randomisation until 
Feb 29, 2004); the post-intervention phase (from 
March 1, 2004, until the data cutoﬀ  on Aug 14, 2009); and 
overall results. Event times during the intervention phase 
were censored at date of death, last follow-up, or 
termination of the intervention phase (Feb 29, 2004), 
whichever occurred ﬁ rst. Participants were included in 
post-intervention phase incidence analyses if they were 
alive, in follow-up, and had not developed breast cancer 
by March 1, 2004. Analyses of overall results began at 
randomisation with censoring deﬁ ned as the earlier of 
death or date of last follow-up. Analyses of breast cancer 
subtypes incorporated censoring at diagnosis of any other 
breast cancer subtype. We assessed heterogeneity of 
hazard ratios across tumour subtypes with competing-
risk models. Analyses of breast cancer mortality included 
all participants, and analysed as per the three phases 
deﬁ ned previously. Women in active follow-up were 
censored at last contact date. Women in passive follow-up 
were censored on Dec 31, 2008 (the last date covered by 
the national death index linkage). To examine eﬀ ects of 
oestrogen over time, we ﬁ tted linear, time-varying hazard 
ratios for randomisation assignment for the intervention 
and postintervention phases separately. We compared 
slopes for each phase with Wald tests.
We examined the inﬂ uence of non-adherence to 
protocol-assigned treatment by censoring events 
6 months after participants ﬁ rst became non-adherent 
(ie, took <80% of study drugs or started non-study 
hormone therapy). Additionally, we included time-
varying weights, which were inversely proportional to the 
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estimated probability of continued adherence, in the 
proportional-hazards models to adjust for changes in the 
distribution of sample characteristics during follow-up.21
In secondary analyses, we tested interactions between 
randomisation assignment and 16 baseline charac teristics 
within the primary Cox model, expanded to include the 
designated baseline factor, randomisation assignment, and 
interaction term(s). We omitted partici pants with missing 
Oestrogen group 
(n=3778)
Placebo group 
(n=3867)
Age at screening (years)
50–59 1223 (32·4%) 1232 (31·9%)
60–69 1740 (46·1%) 1799 (46·5%)
70–79 815 (21·6%) 836 (21·6%)
Ethnic group
White 2945 (78·0%) 3001 (77·6%)
Black 514 (13·6%) 565 (14·6%)
Hispanic 189 (5·0%) 181 (4·7%)
American Indian 31 (0·8%) 18 (0·5%)
Asian/Paciﬁ c Islander 54 (1·4%) 49 (1·3%)
Unknown 45 (1·2%) 53 (1·4%)
Education
Up to high school/GED 1167 (31·2%) 1137 (29·6%)
Post-high school 1630 (43·6%) 1704 (44·4%)
College degree or higher 945 (25·3%) 998 (26·0%)
Family income (US$)
<20 000 891 (24·8%) 913 (24·9%)
20 000–<35 000 1070 (29·8%) 1084 (29·6%)
35 000–<50 000 741 (20·6%) 758 (20·7%)
50 000–<75 000 550 (15·3%) 555 (15·2%)
≥75 000 340 (9·5%) 352 (9·6%)
Marital status
Never married 123 (3·3%) 111 (2·9%)
Divorced or separated 709 (18·8%) 687 (17·9%)
Widowed 777 (20·7%) 785 (20·4%)
Married or cohabiting 2153 (57·2%) 2264 (58·9%)
Body-mass index (kg/m²)
<25 785 (20·9%) 771 (20·1%)
25–<30 1289 (34·3%) 1391 (36·2%)
≥30 1687 (44·9%) 1683 (43·8%)
Smoking status
Never 1988 (53·1%) 1972 (51·5%)
Past 1417 (37·9%) 1489 (38·9%)
Current 336 (9·0%) 370 (9·7%)
Age at menarche (years)
≤11 890 (23·7%) 929 (24·1%)
12–13 2030 (54·1%) 2013 (52·3%)
≥14 833 (22·2%) 908 (23·6%)
Number of term pregnancies
Never pregnant or no term pregnancy 350 (9·3%) 307 (8·0%)
1–2 1033 (27·5%) 1099 (28·6%)
3–4 1527 (40·7%) 1605 (41·7%)
≥5 840 (22·4%) 835 (21·7%)
Age at ﬁ rst birth (years)
Never pregnant or no term pregnancy 350 (10·3%) 307 (8·8%)
<20 822 (24·2%) 872 (24·9%)
20–29 2060 (60·7%) 2128 (60·9%)
≥30 163 (4·8%) 190 (5·4%)
(Continues in next column)
Oestrogen group 
(n=3778)
Placebo group 
(n=3867)
(Continued from previous column)
Number of months breastfed
Never breastfed 1775 (47·8%) 1739 (45·8%)
Breastfed ≤1 year 1412 (38·0%) 1525 (40·1%)
Breastfed >1 year 525 (14·1%) 535 (14·1%)
Benign breast disease
No 2758 (80·2%) 2693 (77·7%)
Yes, one biopsy 500 (14·5%) 550 (15·9%)
Yes, two or more biopsies 183 (5·3%) 222 (6·4%)
First degree female relatives with breast cancer
None 2987 (85·5%) 3084 (86·0%)
One 459 (13·1%) 453 (12·6%)
Two or more 48 (1·4%) 49 (1·4%)
Gail model 5-year risk score
<1·25% 1456 (38·5%) 1505 (38·9%)
1·25–<1·75% 1185 (31·4%) 1220 (31·5%)
≥1·75% 1137 (30·1%) 1142 (29·5%)
Age at hysterectomy (years)
<40 1495 (39·8%) 1501 (39·0%)
40–49 1643 (43·7%) 1662 (43·2%)
50–54 345 (9·2%) 412 (10·7%)
≥55 275 (7·3%) 271 (7·0%)
Bilateral oophorectomy
No 2143 (61·0%) 2094 (58·2%)
Yes 1370 (39·0%) 1507 (41·8%)
Time since menopause (years)
<10 636 (19·9%) 623 (18·8%)
10–<20 1025 (32·1%) 1104 (33·3%)
≥20 1535 (48·0%) 1586 (47·9%)
Hormone therapy use
Never 1929 (51·1%) 1916 (49·6%)
Past 1304 (34·5%) 1373 (35·5%)
Current 544 (14·4%) 575 (14·9%)
Unopposed oestrogen use
Non-user 2006 (53·1%) 2007 (51·9%)
<5 years 938 (24·8%) 1008 (26·1%)
≥5 years 834 (22·1%) 852 (22·0%)
Oestrogen and progesterone use
Non-user 3613 (95·6%) 3668 (94·9%)
<5 years 108 (2·9%) 123 (3·2%)
≥5 years 57 (1·5%) 76 (2·0%)
Data are n (%). GED=general educational development. Some categories do not 
add up to total number of women who consented to extended follow-up due to 
missing data.
Table 1: Baseline characteristics of participants in the Women’s Health 
Initiative trial of conjugated equine oestrogen who consented to 
extended follow-up
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Intervention phase (events on or before Feb 29, 2004)
Post-intervention phase* (events on M
arch 1, 2004–Aug 14, 2009)
O
verall (events to Aug 14, 2009)
Oestrogen (n=5310)
Placebo (n=5429)
HR†‡ (95%
 CI)
Oestrogen (n=4794)
Placebo (n=4877)
HR†§ (95%
 CI)
p
interaction ¶
Oestrogen (n=5310)
Placebo (n=5429)
HR†‡ (95%
 CI)
p
heterogeneity ||
Follow
-up, m
onths
85·8 (77·1–96·8)
86·3 (76·7–97·6)
··
56·7 (42·0–61·0)
57·0 (42·2–61·0)
··
··
141·8 (108·5–154·2)
141·8 (109·1–154·4)
··
··
Invasive breast cancer
104 (0·28%
)
135 (0·35%
)
0·79 (0·61–1·02)
47 (0·26%
)
64 (0·34%
)
0·75 (0·51–1·09)
0·76
151 (0·27%
)
199 (0·35%
)
0·77 (0·62–0·95)
Histology**
0·33
Ductal
60 (0·16%
)
88 (0·23%
)
0·70 (0·51–0·98)
26 (0·14%
)
43 (0·23%
)
0·62 (0·38–1·01)
0·63
86 (0·15%
)
131 (0·23%
)
0·67 (0·51–0·88)
Lobular
18 (0·048%
)
12 (0·031%
)
1·56 (0·75–3·24)
2 (0·011%
)
7 (0·038%
)
0·28 (0·06–1·34)
0·06
20 (0·036%
)
19 (0·033%
)
1·09 (0·58–2·04)
Ductal and lobular
12 (0·032%
)
13 (0·034%
)
0·93 (0·42–2·03)
7 (0·038%
)
5 (0·027%
)
1·38 (0·44–4·34)
0·55
19 (0·034%
)
18 (0·032%
)
1·06 (0·55–2·01)
O
ther
14 (0·037%
)
21 (0·055%
)
0·68 (0·34–1·33)
12 (0·065%
)
9 (0·048%
)
1·37 (0·58–3·25)
0·22
26 (0·047%
)
30 (0·053%
)
0·88 (0·52–1·49)
O
estrogen receptor status**
0·78
Positive
72 (0·19%
)
96 (0·25%
)
0·77 (0·57–1·05)
38 (0·21%
)
53 (0·29%
)
0·72 (0·48–1·10)
0·79
110 (0·20%
)
149 (0·26%
)
0·75 (0·59–0·96)
N
egative
19 (0·051%
)
22 (0·058%
)
0·88 (0·48–1·63)
6 (0·033%
)
9 (0·048%
)
0·70 (0·25–1·96)
0·68
25 (0·045%
)
31 (0·055%
)
0·81 (0·48–1·38)
Progesterone receptor status**
0·34
Positive
57 (0·15%
)
71 (0·19%
)
0·83 (0·58–1·17)
35 (0·19%
)
41 (0·22%
)
0·86 (0·55–1·36)
0·91
92 (0·17%
)
112 (0·20%
)
0·84 (0·63–1·10)
N
egative
32 (0·086%
)
43 (0·11%
)
0·76 (0·48–1·20)
9 (0·049%
)
20 (0·11%
)
0·46 (0·21–1·02)
0·27
41 (0·074%
)
63 (0·11%
)
0·66 (0·45–0·98)
HER2 overexpression**
0·045
Yes
18 (0·048%
)
12 (0·031%
)
1·58 (0·76–3·27)
5 (0·027%
)
4 (0·022%
)
1·32 (0·35–4·94)
0·84
23 (0·041%
)
16 (0·028%
)
1·50 (0·79–2·83)
N
o
53 (0·14%
)
67 (0·18%
)
0·81 (0·56–1·16)
36 (0·20%
)
54 (0·29%
)
0·67 (0·44–1·03)
0·50
89 (0·16%
)
121 (0·21%
)
0·74 (0·56–0·97)
Triple-negative tum
our
0·26
Yes
12 (0·032%
)
8 (0·021%
)
1·54 (0·63–3·79)
4 (0·022%
)
6 (0·032%
)
0·69 (0·19–2·44)
0·30
16 (0·029%
)
14 (0·025%
)
1·14 (0·56–2·34)
N
o
92 (0·25%
)
127 (0·33%
)
0·74 (0·57–0·97)
43 (0·23%
)
58 (0·31%
)
0·75 (0·51–1·12)
>0·99
135 (0·24%
)
185 (0·33%
)
0·74 (0·60–0·93)
Stage**
0·19
Local
67 (0·18%
)
100 (0·26%
)
0·69 (0·51–0·94)
34 (0·18%
)
44 (0·24%
)
0·79 (0·50–1·24)
0·67
101 (0·18%
)
144 (0·25%
)
0·72 (0·56–0·92)
Regional or distant
35 (0·094%
)
31 (0·081%
)
1·15 (0·71–1·86)
13 (0·071%
)
18 (0·097%
)
0·72 (0·36–1·48)
0·30
48 (0·086%
)
49 (0·086%
)
0·98 (0·66–1·46)
Grade**
0·56
W
ell diﬀ erentiated
19 (0·051%
)
26 (0·068%
)
0·74 (0·41–1·33)
11 (0·060%
)
16 (0·086%
)
0·70 (0·32–1·51)
0·91
30 (0·054%
)
42 (0·074%
)
0·72 (0·45–1·16)
M
oderately 
diﬀ erentiated
31 (0·083%
)
52 (0·14%
)
0·61 (0·39–0·96)
20 (0·11%
)
31 (0·17%
)
0·65 (0·37–1·14)
0·91
51 (0·092%
)
83 (0·15%
)
0·62 (0·44–0·88)
Poorly diﬀ erentiated
29 (0·078%
)
40 (0·10%
)
0·75 (0·46–1·21)
14 (0·076%
)
13 (0·070%
)
1·11 (0·52–2·37)
0·40
43 (0·077%
)
53 (0·093%
)
0·83 (0·55–1·24)
Tum
our size (cm
)**
0·06
≤1
31 (0·083%
)
51 (0·13%
)
0·63 (0·40–0·98)
11 (0·060%
)
21 (0·11%
)
0·53 (0·26–1·11)
0·70
42 (0·075%
)
72 (0·13%
)
0·60 (0·41–0·87)
1–<2
35 (0·094%
)
52 (0·14%
)
0·69 (0·45–1·06)
16 (0·087%
)
21 (0·11%
)
0·78 (0·41–1·50)
0·77
51 (0·092%
)
73 (0·13%
)
0·71 (0·50–1·02)
≥2
25 (0·067%
)
23 (0·060%
)
1·10 (0·63–1·95)
16 (0·087%
)
16 (0·086%
)
0·99 (0·49–1·97)
0·79
41 (0·074%
)
39 (0·069%
)
1·05 (0·68–1·63)
Positive lym
ph nodes**
0·14
N
o
61 (0·16%
)
93 (0·24%
)
0·68 (0·49–0·94)
27 (0·15%
)
41 (0·22%
)
0·67 (0·41–1·09)
0·94
88 (0·16%
)
134 (0·24%
)
0·67 (0·51–0·88)
Yes
32 (0·086%
)
28 (0·073%
)
1·16 (0·70–1·92)
11 (0·060%
)
16 (0·086%
)
0·69 (0·32–1·49)
0·27
43 (0·077%
)
44 (0·077%
)
0·98 (0·64–1·49)
All-cause m
ortality 
after breast cancer
7 (0·018%
)
12 (0·031%
)
0·60 (0·22–1·48)
23 (0·087%
)
38 (0·14%
)
0·62 (0·36–1·03)
0·92
30 (0·046%
)
50 (0·076%
)
0·62 (0·39–0·97)
Breast cancer deaths
4 (0·011%
)
9 (0·023%
)
0·45 (0·12–1·37)
2 (0·008%
)
7 (0·026%
)
0·29 (0·04–1·21)
0·66
6 (0·009%
)
16 (0·024%
)
0·37 (0·13–0·91)
Data are m
edian (IQ
R) or n (%
 per year). HR=hazard ratio. *Post-intervention phase includes data obtained during the extended follow
-up (after M
arch 31, 2005); 3778 (77·9%
) of 4851 eligible participants random
ly allocated to oestrogen and 3867 (78·4%
) 
of 4935 eligible participants random
ly allocated to placebo consented to extended follow
-up. †From
 a proportional hazards m
odel, stratiﬁ ed by age group (50–54, 55–59, 60–69, and 70–79 years) and dietary m
odiﬁ cation random
isation group. ‡Tim
e to 
event m
easured from
 date of random
isation. §Tim
e to event m
easured from
 M
arch 1, 2004. ¶p
interaction  based on tests for equality of the intervention and post-intervention phase hazard ratios in a proportional hazards m
odel, stratiﬁ ed by age group (50–54, 
55–59, 60–69, and 70–79 years), dietary m
odiﬁ cation random
isation arm
, and trial phase (tim
e dependent), w
ith tim
e to event m
easured from
 date of random
isation. ||p
heterogeneity  from
 a com
peting risks analysis that tested w
hether hazard ratios diﬀ ered 
betw
een tum
our types. **Hazard ratios for a speciﬁ c tum
our characteristic are from
 proportional hazards m
odel in w
hich incidence of tum
our w
ith alternate characteristics w
ere censored; tum
our characteristics w
ere m
issing for the follow
ing num
bers of 
cases for histology (none in the active group vs one in the placebo group), oestrogen receptor status (16 vs 19), progesterone receptor status (18 vs 24), HER2 overexpression (39 vs 62), stage (tw
o vs six), grade (27 vs 21), tum
our size (ten vs 11), and positive 
lym
ph nodes (20 vs 21). 11 tum
ours of indeterm
inate size w
ere reported (seven in the active group vs four in the placebo group). 
Table 2: Associations betw
een conjugated equine oestrogen and breast cancer incidence and m
ortality during and after the intervention in the W
om
en’s H
ealth Initiative random
ised trial
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values from the corresponding analysis. No adjustment for 
multiple testing was made; at most, one interaction was 
expected to be signiﬁ cant by chance alone.
All analyses were done with SAS version 9.1.3 and 
ﬁ gures were drawn with R 2.11. All p values are two-sided 
and p values of 0·05 or less were regarded as signiﬁ cant 
at the 0·05 level. The WHI study is registered with 
ClinicalTrials.gov, number NCT00000611.
Role of the funding source
The WHI Project Oﬃ  ce at the US National Heart, Lung, 
and Blood Institute (NHLBI) reviewed and approved the 
ﬁ nal manuscript but had no other role in the preparation 
of this report. Decisions about study design, data 
collection and analysis, result interpretation, manuscript 
preparation, and the decision to submit the manuscript 
for publication resided with committees comprised of 
WHI investigators that included NHLBI representatives. 
AKA had access to the raw data. The corresponding 
author had full access to all of the data and the ﬁ nal 
responsibility to submit for publication.
Results
Baseline breast cancer risk factors in women who 
consented to extended follow-up were much the same 
as those of the original cohort18 and much the same 
between randomised groups, apart from a small 
imbalance in bilateral oophorectomy and benign breast 
disease (table 1). During the intervention phase, 80–90% 
of par ticipants had mammograms every year with equiva-
lent frequencies in the two treatment groups.17,22 
3894 (81·2%) of 4794 of women in the oestrogen group 
and 3965 (81·3%) of 4877 controls had at least one 
mammogram after the trial intervention was stopped.
Figure 1: Kaplan-Meier estimates of cumulative hazards of invasive breast cancer in the WHI randomised trial of conjugated equine oestrogen with the intention-to-treat principle (A) and 
with adjustments for adherence (B)
Background shading shows the distribution of the duration of intervention (in quintiles). HR=hazard ratio.
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We previously reported18 that 53·8% of 10 739 partici-
pants had stopped study drugs by trial termination with 
very similar frequencies noted between randomisation 
groups. By that time, 5·7% of 5310 women in the 
oestrogen group and 9·1% of 5429 controls had started 
hormones provided by their health-care providers.18 Of 
7472 participants in extended follow-up with available 
data, 604 (8·1%) reported use of hormones after 
intervention, with slightly more in the oestrogen group 
than the placebo group (334 [9·0%] of 3699 in the 
oestrogen group vs 270 [7·2%] of 3773 controls; p=0·003).
In the intention-to-treat analyses, data were available 
for a median follow-up of 7·2 years (IQR 6·4–8·1) from 
randomisation until early termination of the trial 
intervention, a median follow-up of 4·7 years (3·5–5·1) 
after intervention, and a median of 11·8 years (9·1–12·9) 
follow-up overall. In these analyses, use of oestrogen was 
associated with lower overall invasive breast cancer 
incidence (151 events, 0·27% per year) compared with 
placebo (199 events, 0·35% per year; HR 0·77, 95% CI 
0·62–0·95; p=0·02;19 table 2, ﬁ gure 1), with no diﬀ erence 
between intervention and post-intervention hazard ratios 
(pinteraction=0·76). Adjust ment for the small imbalances 
noted in the characteristics of extended follow-up 
participants had no appreciable eﬀ ect on the post-
intervention results. We noted non-signiﬁ cant increasing 
trends in oestrogen HRs by time since randomisation 
(pslope=0·19) and by time since trial cessation (pslope=0·32).
Median duration of study drug use was 5·9 years 
(IQR 2·5–7·3) and median time to non-adherence (ie, 
taking <80% of study pills or starting other hormone 
therapy) was 3·5 years (1·5–6·5). Sensitivity analyses 
adjusting for non-adherence yielded a stronger 
association between oestrogen use and lower breast 
cancer risk overall (HR 0·68, 95% CI 0·49–0·95; ﬁ gure 1), 
which seemed even higher when restricted to the 
intervention period (0·58, 0·39–0·84).
In analyses of tumour characteristics (table 2), oestrogen 
use was associated with a reduced risk of inﬁ ltrating ductal 
carcinoma (HR 0·67, 95% CI 0·51–0·88) compared with 
placebo but not inﬁ ltrating lobular cancers; however, the 
test for heterogeneity was not signiﬁ cant (p=0·33). Hazard 
Figure 2: Kaplan-Meier estimates of cumulative hazards for breast cancer deaths (A) and all-cause mortality after breast cancer (B) in the WHI randomised trial of conjugated equine oestrogen
Background shading shows the distribution of the duration of intervention (in quintiles). HR=hazard ratio.
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Figure 3: Hazard ratios for 
invasive breast cancer 
incidence by baseline 
characteristics in the 
WHI trial of conjugated 
equine oestrogen
Data are n (% per year) 
unless otherwise stated. 
Age (years)    0·98
   50–59 43 (0·24%) 54 (0·30%) 0·80 (0·54–1·20) 
   60–69 68 (0·27%) 95 (0·37%) 0·73 (0·54–1·00) 
   70–79 40 (0·32%) 50 (0·39%) 0·81 (0·53–1·23) 
Ethnic group    0·09
   White 123 (0·29%) 154 (0·36%) 0·81 (0·64–1·02) 
   Black 15 (0·19%) 35 (0·41%) 0·47 (0·25–0·86) 
Body-mass index    0·49
   <25 24 (0·21%) 30 (0·26%) 0·79 (0·46–1·35) 
   25–<30 36 (0·19%) 61 (0·30%) 0·62 (0·41–0·94) 
   ≥30 91 (0·37%) 106 (0·43%) 0·86 (0·65–1·14) 
Current smoker        0·49 
   No 139 (0·28%)  178 (0·35%)  0·79 (0·63–0·98)   
   Yes 10 (0·19%)  19 (0·33%)  0·59 (0·28–1·28)   
Age at ﬁrst birth (years)      0·56 
   Never/no term pregnancy 11 (0·22%)  17 (0·36%)  0·65 (0·30–1·40)   
   <20  34 (0·27%)  40 (0·31%)  0·86 (0·54–1·36)   
   20–30  83 (0·28%)  104 (0·34%)  0·82 (0·61–1·09)   
   ≥30 6 (0·26%)  13 (0·48%)  0·56 (0·21–1·50)   
History of benign breast disease        0·01 
   No previous biopsy 93 (0·23%)  146 (0·38%)  0·61 (0·47–0·79)   
   One or more previous biopsy  38 (0·40%)  37 (0·34%)  1·22 (0·77–1·92)   
First degree relative with breast cancer     0·02 
   No  102 (0·23%)  153 (0·34%)  0·68 (0·53–0·88)   
   Yes  39 (0·54%)  32 (0·44%)  1·25 (0·78–2·01)   
Gail risk score       0·22 
   <1·25  47 (0·21%)  66 (0·29%)  0·72 (0·49–1·04)   
   1·25–1·75  38 (0·22%)  64 (0·37%)  0·60 (0·40–0·90)   
   ≥1·75  66 (0·41%)  69 (0·42%)  0·97 (0·69–1·36)   
Moderate or severe vasomotor symptoms      0·74 
   No  121 (0·27%)  162 (0·35%)  0·76 (0·60–0·96)   
   Yes  27 (0·29%)  33 (0·34%)  0·83 (0·50–1·39)   
Bilateral oophorectomy        0·55 
   No  99 (0·32%)  118 (0·38%)  0·81 (0·62–1·06)   
   Yes  43 (0·21%)  68 (0·31%)  0·71 (0·48–1·04)   
Time since menopause (years)       0·68 
   <10 22 (0·24%)  28 (0·31%)  0·76 (0·44–1·33)   
   10−20 32 (0·21%)  50 (0·31%)  0·67 (0·43–1·05)   
   ≥20  71 (0·31%)  89 (0·38%)  0·82 (0·60–1·12)   
Previous oestrogen use       0·95 
   No  84 (0·28%)  109 (0·36%)  0·76 (0·57–1·02)   
   Yes  67 (0·26%)  90 (0·33%)  0·77 (0·56–1·06)   
Oestrogen duration (years)       0·56 
   Never used  84 (0·28%)  109 (0·36%)  0·76 (0·57–1·02)   
   <2  18 (0·23%)  29 (0·35%)  0·66 (0·37–1·20)   
   2−5 19 (0·25%)  23 (0·30%)  0·85 (0·46–1·56)   
   >5 30 (0·29%)  38 (0·35%)  0·84 (0·52–1·36)   
Age at ﬁrst oestrogen use (years)      0·58 
   Never used  84 (0·28%)  109 (0·36%)  0·76 (0·57–1·02)   
   <40  15 (0·28%)  16 (0·29%)  0·88 (0·43–1·79)   
   40−50 37 (0·28%)  51 (0·36%)  0·77 (0·50–1·17)   
   >50  15 (0·21%)  23 (0·31%)  0·67 (0·35–1·29)   
Gap time (years)       0·13 
   <5  69 (0·28%)  199 (0·35%)  0·89 (0·66–1·20)   
   ≥5 56 (0·25%)  199 (0·35%)  0·65 (0·48–0·89)   
Bilateral oophorectomy/previous oestrogen use     0·90 
   No/No  61 (0·32%)  71 (0·39%)  0·81 (0·57–1·14)   
   No/Yes  15 (0·19%)  29 (0·32%)  0·62 (0·33–1·16)   
   Yes/No  38 (0·31%)  47 (0·38%)  0·82 (0·53–1·26)   
   Yes/Yes  28 (0·23%)  39 (0·30%)  0·77 (0·47–1·25)   
Overall eﬀect 151 (0·27%)  199 (0·35%)  0·77 (0·62–0·95)  0·02 
Oestrogen group Placebo group  Hazard ratio (95% CI) pinteraction
(n=5310) (n=5429) 
0·25 1·000·50 2·00
Favours oestrogen Favours placebo
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ratios for hormone receptor-positive tumours and hormone 
receptor-negative tumours were much the same. We noted 
a reduced risk for HER2-negative tumours (0·74, 0·56–0·97) 
but not HER2-positive tumours (1·50, 0·79–2·83) in 
women who received oestrogen compared with placebo 
(pheterogeneity=0·045), although missing HER2 data were 
common. Compared with placebo, we noted fewer small 
and node-negative tumours but no reduction in the 
number of large tumours (≥2 cm) or node-positive tumours 
in the oestrogen group, but comparisons between subtypes 
did not reach signiﬁ cance.
In analyses starting at randomisation (table 2 and 
ﬁ gure 2), fewer women diagnosed with breast cancer died 
in the oestrogen group (30 deaths, 0·046% per year) com-
pared with the placebo group (50 deaths, 0·076% per year; 
HR 0·62, 95% CI 0·39–0·97; p=0·04). Of these deaths, six 
were directly attributed to breast cancer in the oestrogen 
group (0·009% per year) compared with 16 in the placebo 
group (0·024% per year; 0·37, 0·13–0·91; p=0·03).
Subgroup analyses provided a mostly consistent pattern 
of lower breast cancer incidence with oestrogen use 
(ﬁ gure 3). Of 16 interactions tested, two were nominally 
statistically signiﬁ cant: history of benign breast disease 
(p=0·01) and ﬁ rst degree family history of breast cancer 
(p=0·02). In both of these analyses, evidence for lower 
breast cancer incidence was restricted to women without 
these risk factors. No interactions were reported with age 
(p=0·98), body-mass index (p=0·49), Gail model risk 
score (p=0·22), oophorectomy status (p=0·55), years 
since menopause onset (p=0·68), previous oestrogen use 
(p=0·95), or vasomotor symptoms (p=0·74).
Of women who ﬁ rst used hormone therapy 5 years 
or more after menopause (ie, gap time ≥5 years), the 
estimated eﬀ ect of oestrogen (HR 0·65, 95% CI 0·48–0·89) 
seemed lower than that for women who started hormone 
therapy sooner after menopause (0·89, 0·66–1·20) but the 
interaction was not signiﬁ cant (p=0·13).
Discussion
Use of oestrogen for a median of 5·9 years in 
postmenopausal women with hysterectomy in the WHI 
randomised trial was associated with a signiﬁ cant 
reduction in incidence of invasive breast cancer, a 
reduction that continued for the median 4·7 years of 
follow-up after discontinuation of intervention. 
Adjustment for adherence suggested somewhat stronger 
protective eﬀ ects of oestrogen therapy compared with 
placebo. Potential eﬀ ect modiﬁ cation with benign breast 
disease (p=0·01) and family history of breast cancer 
(p=0·02) suggests that these reductions might not apply 
to women at increased risk. We noted a signiﬁ cant 
reduction in breast cancer-related mortality and all-cause 
mortality after breast cancer diagnosis with oestrogen 
use, but the number of such deaths was small.
Although many observational studies have reported an 
increased risk of breast cancer with oestrogen use,2–5 
some have reported lower risks.6,23 In previous studies 
reporting an adverse eﬀ ect of such therapy on breast 
cancer, most2–5,8 but not all,5,9 showed an increased risk of 
breast cancer only after prolonged (>5 years) oestrogen 
use. In this trial, with substantial variation in exposure 
length (median duration of the intervention 5·9 years 
[range <1–10 years]; median adherent time 3·5 years; 
and 2291 [21%] of 10 739 partici pants reporting previous 
oestrogen use for >5 years at baseline), we noted no 
time-trends in terms of duration of use or time since 
cessation and no interactions with previous oestrogen 
use, although the power for interaction tests was low 
(panel). The continued, postintervention eﬀ ect of 
oestrogen on breast cancer incidence is akin to that 
reported for other hormone-targeted drugs shown to 
reduce breast cancer incidence.33,34
Panel: Research in context
Systematic review
Conjugated equine oestrogen was approved for management of climacteric symptoms in 
several countries in the early 1940s. By the 1990s, about 40% of postmenopausal women 
in the USA and UK were receiving hormone therapy (oestrogen alone or oestrogen plus 
progesterone).24–26 However, the risks and beneﬁ ts of this commonly used therapy had 
never been established in a clinical trial setting. Against this background, scientists at the 
US National Institutes of Health, working in conjunction with experts in a number of 
disciplines, developed the Women’s Health Initiative (WHI) hormone therapy programme 
to meet this unmet need with potential implications for a large number of 
postmenopausal women in the USA and around the world.27
The WHI hormone therapy programme consisted of two full-scale randomised, 
placebo-controlled clinical trials to separately assess the eﬀ ect of oestrogen alone and 
oestrogen plus progesterone on chronic disease in postmenopausal women with and 
without previous hysterectomy, respectively, at 40 clinical sites in the USA. When the WHI 
trials were developed, observational study evidence suggested that oestrogen, alone or 
with progesterone, would modestly increase breast cancer risks2–5 but the cancers would 
have a favourable prognosis.3–5
The results from the WHI randomised, placebo-controlled trial of oestrogen alone 
contradicts most previous observational studies in that oestrogen use was associated 
with reduced breast cancer incidence and reduced breast cancer-associated mortality. 
Previous eﬀ orts to reconcile these results have pointed to the issue of timing of ﬁ rst 
hormone therapy.28,29 Additionally, some of the diﬀ erences between previous 
observational studies and the present randomised clinical trial results might reﬂ ect 
variation in mammography frequency in observational study populations. In that setting, 
oestrogen users more frequently have mammography, leading to more common breast 
cancer diagnosis at an early stage. The WHI oestrogen-alone ﬁ ndings also diﬀ er from 
those seen in the WHI randomised trial assessing oestrogen plus progesterone in women 
without previous hysterectomy in which combined hormone therapy signiﬁ cantly 
increased breast cancer incidence and breast cancer mortality.30–32
Interpretation
Our ﬁ ndings provide reassuring evidence about breast safety of oestrogen use for 
climacteric symptom management in postmenopausal women with hysterectomy for 
durations consistent with those reported in this trial. Although a reduced risk of breast 
cancer incidence and mortality was noted in recipients of oestrogen, these ﬁ ndings do 
not support its use for breast cancer risk reduction in light of the lack of beneﬁ t for 
populations at higher risk, the adverse eﬀ ects on stroke and venous thromboembolism,18 
and the increased risk reduction available with other drugs.
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Many observational studies report increased breast 
cancer risk with oestrogen alone in normal weight but 
not overweight or obese women.4,5,8 We noted no eﬀ ect 
modiﬁ cation with body-mass index; oestrogen hazard 
ratios were less than one in normal weight, overweight, 
and obese women.
Use of mammography is a potential source of 
confounding in observational studies.35 In clinical 
practice, women who take hormone therapy have 
mammograms more regularly than untreated women36 
and screened populations have an increased rate of breast 
cancer detection,37,38 potentially explaining the increased 
breast cancer risk in oestrogen users noted in previous 
studies that did not assess screening. Controlling for 
ongoing screening in observational studies is unusual 
and not straightforward because it depends on adequate 
data collection and modelling, and the assumption that 
mammography use is not an intermediate variable of 
exposure and disease.39,40
Detection bias is an unlikely explanation for our results. 
Mammography rates were protocol-deﬁ ned and very 
similar between randomisation groups.17,22 Further more, 
oestrogen use has little eﬀ ect on breast density41 
or detection of breast cancer.22 Finally, the signiﬁ cant 
reduction in breast cancer mortality reported with 
oestrogen use provides strong evidence against the 
possibility that the risk reduction noted was an artifact of 
oestrogen eﬀ ects on screening,40 because a delay in 
detection would be expected to increase mortality.
Favourable eﬀ ects of use of oestrogen alone on 
breast cancer survival, measured from cancer diagnosis, 
have been seen in some10–12 but not all2,7,13–16 reports. 
Measurement of survival by time since diagnosis might 
introduce lead-time bias in hormone therapy studies if 
screening rates varied between hormone users and non-
users. Studies of mostly oestrogen alone use on breast 
cancer mortality, measured from start of hormone therapy 
have provided mixed results with favourable,10–12 neutral,13–15 
and unfavourable2,7 associations reported. Our results, 
measured from randomisation (although still imprecise) 
provide important new evidence that oestrogen use for 
about 5 years reduces breast cancer mortality, supporting 
a favourable association with breast cancer incidence.
A reduction in breast cancer incidence with conjugated 
equine oestrogen is biologically plausible. Although such 
oestrogen is a recognised mitogen that usually stimulates 
mammary cell proliferation and inhibits apoptosis 
through activation of the oestrogen receptor,1 both 
preclinical42–46 and clinical45 ﬁ ndings suggest that after 
long-term oestrogen deprivation, adaptive changes in 
mammary tumour gene expression proﬁ les render 
tumours paradoxically susceptible to oestrogen-induced 
apoptosis.43,44 Although the mechanisms are complex and 
not wholly understood,46 preclinical studies suggest 
involvement of the Fas/Fas L extrinsic (receptor-mediated) 
death regulatory pathway47 and the intrinsic (mitochon-
drial) apoptotic pathway, mediated through increased 
expression of several proapoptotic proteins including 
P53-unregulated modulator of apoptosis.48,49
Eﬀ orts to reconcile the original ﬁ ndings of this trial17 
with observational study results suggested that the time 
from menopause to ﬁ rst hormone use (gap time) is a 
potential modulator of hormone therapy’s inﬂ uence on 
breast cancer risk.28 In the parallel WHI randomised 
clinical trial29 and the observational Million Women 
Study,5 women starting oestrogen plus progesterone 
use with a short gap time were at increased breast 
cancer risk. For use of oestrogen alone, the Million 
Women Study investigators reported no increased 
incidence in breast cancer with oestrogen use starting 
5 years or more from menopause but an increased risk 
with a shorter gap time.5 In these analyses, oestrogen 
hazard ratios were lower than 1 for early initiation (gap 
time <5 years) and late initiation (≥5 years). We noted a 
somewhat greater inﬂ uence in women starting 
oestrogen therapy 5 years or more after meno pause, 
but the interaction with gap time was not statistically 
signiﬁ cant.
Figure 4: Cumulative hazards, adjusted for age and ethnic group, of invasive breast cancer by random 
allocation in the WHI trials of conjugated equine oestrogen alone and conjugated equine oestrogen plus 
medroxyprogesterone acetate trials derived from Chlebowski and colleagues32
HR=hazard ratio.
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Although breast cancer incidence and related mortality 
were lower for women who took oestrogen alone than for 
controls, our ﬁ ndings do not support oestrogen use for 
breast cancer risk reduction because subgroup analyses 
suggest the beneﬁ t might not apply to populations at 
increased breast cancer risk. Additionally, other hormone-
targeted drugs have a substantially greater inﬂ uence on 
breast cancer than does oestrogen.33,34,50,51 However, our 
ﬁ ndings, together with a relatively balanced risk–beneﬁ t 
proﬁ le for clinical events,18,52 provide reassurance about 
breast cancer safety for postmenopausal women with 
previous hysterectomy who receive unopposed oestrogen 
to reduce climacteric symptoms for durations equivalent 
to those reported in this trial.
Tamoxifen, raloxifene, and exemestane all provide 
greater breast cancer risk reduction than oestrogen, 
but have important limitations. The selective oestrogen 
receptor modulators tamoxifen and raloxifene reduce 
risk of breast cancer and fractures but increase climac-
teric symptoms and have adverse eﬀ ects on stroke, blood 
clots, and endometrial cancer, leading to an unfavourable 
risk–beneﬁ t proﬁ le in most postmenopausal women.33,53 
Exemestane, an aromatase inhibitor that lowers 
oestro gen concentrations, also substantially reduces 
breast cancer risk.34 However, aromatase inhibitors cause 
bone loss and increase climacteric symptoms and 
arthralgias,54 exerting a greater inﬂ uence when started 
soon after menopause.55 The mechanisms through 
which exogenous oestrogens, tamoxifen, raloxifene, and 
aromatase inhibitors all reduce breast cancer risk are not 
known but clearly warrant further study.
Study strengths include the randomised, double-
masked, placebo-controlled prospective design with 
breast cancer as the designated primary safety outcome, 
a large sample size, high-quality outcomes ascer-
tainment, and protocol-required mammography 
throughout most of the follow-up period. Median time 
to non-adherence to intervention was only 3·5 years, 
which was much shorter than that noted in studies 
reporting increased risks. However, any bias arising 
from poor adherence would probably dilute the 
diﬀ erences between random isation groups over the 
duration of follow-up, as the adherence-adjusted 
analyses conﬁ rmed. Small numbers of breast cancer 
deaths, some attrition associated with re-consenting for 
extended follow-up, and a median of only 4·7 years of 
post-intervention follow-up should also be noted. The 
trial assessed only one dose and schedule of oral 
conjugated equine oestrogens; whether these ﬁ ndings 
apply to lower doses, other oestrogen preparations, or 
longer durations of use is not known.
Major diﬀ erences exist in WHI trial ﬁ ndings between 
oestrogen only therapy in women with previous hyster-
ectomy and those of the parallel WHI randomised trial 
of oestrogen plus medroxyprogesterone acetate in 
women with an intact uterus. Whereas oestrogen-alone 
treatment was associated with reduced breast cancer 
incidence and reduced breast cancer mortality, combined 
hormone therapy increased breast cancer incidence,29,52 
delayed breast cancer diagnosis,56 and increased breast 
cancer mortality.48 The biological basis for this diﬀ erence 
is unknown. The comparability of breast cancer 
incidence rates for the placebo groups in the two trials 
(ﬁ gure 4) suggests that diﬀ erences in hormone therapy, 
rather than hysterectomy, is the primary determinant. 
Changes in the serum proteome in response to oestrogen 
and combined hormone therapies are generally quite 
similar but diﬀ erences have been identiﬁ ed that could 
inﬂ uence breast cancer risk, including those in NOTCH2 
and some IGF binding proteins.57
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